EP0411624A2 - Saccharide derivatives of protocatechualdehyde - Google Patents
Saccharide derivatives of protocatechualdehyde Download PDFInfo
- Publication number
- EP0411624A2 EP0411624A2 EP90114847A EP90114847A EP0411624A2 EP 0411624 A2 EP0411624 A2 EP 0411624A2 EP 90114847 A EP90114847 A EP 90114847A EP 90114847 A EP90114847 A EP 90114847A EP 0411624 A2 EP0411624 A2 EP 0411624A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- methyl
- general formula
- protocatechualdehyde
- saccharide derivatives
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(C(C1O)O)OC2C1OC(c(cc1)cc(O)c1O)OC2 Chemical compound *C(C(C1O)O)OC2C1OC(c(cc1)cc(O)c1O)OC2 0.000 description 2
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
Definitions
- the present invention relates to the saccharide derivatives of protocatechualdehyde, the method for preparing thereof, and the use of said derivatives as an anti-inflammatory agent.
- protocatechualdehyde even when administered at a low concentration level, shows a suitable effect of an anti-inflammatory agent that has a pharmacological action of inhibiting granuloma growth, adjuvant arthritis, leukocytic migration, blood platelet agglutination, and the like; however, in the case of in vivo tests, a large dose of protocatechualdehyde must be administered over a long period due to a higher metabolic rate, in order to obtain a significant pharmacological effect, and moreover, the aldehyde portion of the protocatechualdehyde compound poses excitation and oxidizability problems.
- the present inventors as a result of research and development of a drug which is administered to live organ requiring only a small dosage to show a significant pharmacological effect with the minimum side-effect, have found that this object can be achieved by the novel saccharide derivatives of protocatechualdehyde having its aldehyde portion reacted to saccharides.
- a primary object of the present invention is to provide novel saccharide derivatives of protocatechualdehyde requiring administration of only a small dosage to show favorable pharmacological effects, such as an antiinflammatory effect, with the minimum side-effect, together with the method for preparation and use of said derivatives.
- Other objects of the present invention will be found out from what is described below.
- Fig. 1 through Fig. 8 show the infrared absorption spectra of the following compounds of the present invention:
- the present invention provides novel saccharide derivatives of protocatechualdehyde represented by general formula (I): wherein R1 represents a hydrogen atom or a benzoyl group and R2 represents an alkyl group.
- the saccharides shown in the above general formula (I) are hexose that includes for example glucose, mannose, galactose, talose, allose, altrose, idose and gulose. Among them, glucose, galactose and mannose are preferable.
- R2 represents an alkyl group protecting the hydroxyl group in 1-position of saccharides.
- R2 represents an alkyl group containing 1 to 4 carbon atoms, more preferably 1 to 2 carbon atoms.
- the saccharide derivatives of protocatechualdehyde of the present invention represented by the above general formula (I) include, for example, the following compounds: Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)- ⁇ -D-glucopyranoside (Ia1) Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)- ⁇ -D-glucopyranoside (Ib1) Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)- ⁇ -D-glucopyranoside (Ia2) Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)- ⁇ -D-glucopyranoside (Ib2) Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)- ⁇ -D-glucopyranoside (Ib2) Methy
- the saccharide derivatives of protocatechualdehyde of the present invention may be ⁇ -form, ⁇ -form, or mixtures thereof.
- the saccharides in the derivatives of the present invention may be D-form, L-form or mixtures thereof.
- the saccharide derivatives of protocatechualdehyde of the present invention (hereafter called compounds of the present invention) can be produced advantageously by the following method.
- the acetalization of the above method for preparing is carried out by dissolving 3,4-dibenzoyloxybenzaldehyde (II) in a lower alcohol(IV) such as methanol or ethanol, then by adding a catalytic amount of p-toluenesulfonic acid or the like and by heating the mixture for 2 to 5 hours under reflux. From the reaction mixture, the lower alcohol (IV) is evaporated, and the residue, or the acetalized compound (V) isolated from the said residue, is reacted with the saccharide derivatives (III).
- a lower alcohol(IV) such as methanol or ethanol
- the said saccharide derivatives include, for example, 1-O-methyl ⁇ -D-glucopyranoslde, 1-O-methyl- ⁇ -D-glucopyranoside, 1-O-methyl- ⁇ -D-galactopyranoside, 1-O-methyl- ⁇ -D-galactopyranoside, 1-O-methyl- ⁇ -D-galactopyranoside, 1-O-methyl- ⁇ -D-mannopyranoside, 1-O-methyl- ⁇ -D-mannopyranoside, 1-O-ethyl- ⁇ -D-glucopyranoside, 1-O-n-propyl- ⁇ -D-glucopyranoslde, 1-O-i-propyl- ⁇ -D-glucopyranoside, and 1-O-n-butyl- ⁇ -D-glucopyranoside.
- Acetalized compounds of 3,4-dibenzoyloxybenzaldehyde (II) is reacted with saccharide derivatives (III) in an organic solvent in the presence of an acid catalyst at 55-65 o C, and this temperature is eventually raised to 80-100 o C, while the alcoholic content which is set free is separated and removed and the solvent is refluxed under reduced pressure.
- an acid catalyst usually absolute dimethylformamide or the like is used.
- p-toluenesulfonic acid or the like is used as the acid catalyst.
- the compound (Ia) of the present invention is obtained by evaporating the organic solvent under reduced pressure, then dissolving the residue in an organic solvent such as ethyl acetate or the like, removing the acid catalyst through washing with a saturated sodium hydrogencarbonate aqueous solution or the like, further removing the organic solvent if necessary, and finally, purifying the product through recrystallization or the like.
- the compound (Ib) of the present invention is obtained by the ammonolysis of the compound (Ia) of the present invention.
- the ammonolysis is carried out by suspending the compound (Ia) of the present invention in an alcohol such as absolute methanol and then bubbling ammonia gas into the mixture at the room temperature.
- the ammonia gas is bubbled in slowly to keep the temperature from rising by heat generation.
- the 3,4-dibenzoyloxybenzaldehyde (II) used as a starting material is obtained by dissolving, for example, protocatechualdehyde and triethylamine in dichloromethane and then adding benzoyl chloride dropwise while stirring in an icy water bath.
- the compounds of the present invention can be administered orally, intra-intestinally, or by injection in a variety of pharmaceutical preparation forms and formulations combined with medically recognized carriers and/or adjuvants.
- two or more compounds of the present invention may be used together in a mixture, or may be used by combinding with any other pharmaceutically active component.
- the compounds of the present invention can be administered orally or non-orally, it is possible to take different drug forms suitable for respective administration modes. Furthermore, the compounds of the present invention can be supplied on an administration unit form, wherein as long as an effective dosage is contained, a variety of preparation forms are permissible, such as powder, granule, tablet, sugar coated tablet, capsule, suppository, suspension, fluid, emulsion, ampule and injection forms.
- the drugs of the present invention should be understood as suppliable by any known means of pharmaceutical preparation.
- the content of compounds of the present invention (active component) in the preparation of the present invention can vary widely from 0.01 to 100%, preferably from 0.1 to 70% (by weight).
- the drugs of the present invention is administered to humans and animals orally or non-orally.
- oral administration includes sublingual administration
- non-oral administration includes subcutaneous, intramuscular and intravenous injections and drip infusions.
- the drug of the present invention may be administered in an amount outside the range of the dosage indicated below, but in the case of humans, the general oral dosage of compounds of the present invention is 0.1-500 mg per 1 kg of weight per day, preferably 0.5-200 mg, and the general non-oral dosage is 0.01-200 mg per 1 kg of weight per day, preferably 0.1-100 mg, wherein the daily amount is administered in 1-4 divided dosages.
- the compounds of the present invention are novel compounds having an inhibiting activity against granuloma growth, a lower toxicity than protocatechualdehyde, and a pharmaceutical effect even with a small dosage.
- the compound of the present inven tion are suitable as an anti inflammatory agent for the remedy of chronic articular rheumatism and the like when administered singly or as an active component of pharmaceutical preparations.
- Example 1(4) an ammonolysis was carried out by using 14.0g of the methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)- ⁇ -D-galactopyranoside obtained in the above (1).
- Example 1(4) an ammonolysis was carried out by using 3.83g of the methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)- ⁇ -D-mannopyranoside obtained in the above (1).
- Example 1(4) an ammonolysis was carried out by using 4.15g of the methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)- ⁇ -D-glucopyranoside obtained in the above (1).
- the residue derived from evaporation of methanol was isolated by a silica gel column chromatography. Ethyl acetate/benzene (3/1 v/v) was first used as the solvent, then acetone was used.
- This example shows the results of a test on the toxicity and pharmacological characteristics of the compounds of the present invention.
- the compounds of the present invention methyl-4,6-O-(3′,4′-dihydroxybenzylidene)- ⁇ -D-glucopyranoside [(Ib1)] and methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)- ⁇ -D-glucopyranoside [(Ia1)] were used as test samples.
- protocatechualdehyde(PAL) was employed.
- test drugs dispersed In 0.3% CMC aqueous solution at a rate of 20 mg/ml for oral administration and the test drugs dissolved in 10% ethanol isotonic sodium chloride solution at a rate of 200 mg/ml for intraperitoneal administration were applied using gastric probes and syringes, respectively.
- the results are shown in Table 1.
- the LD50 value of indomethacin which was used as a positive control in this test, is 30.2 mg/kg for male mice and 29 mg/kg for male rats, and therefore, indomethacin is more toxic than both PAL and the compounds of the present invention.
- This example shows the pharmaceutical preparation of compounds of the present invention.
- Compound of the present invention [methyl-4,6-O-(3′,4′-dihydroxybenzylidene)- ⁇ -D-glucopyranoside] 10 weight parts Heavy magnesium oxide 15 weight parts Lactose 75 weight parts were evenly mixed to obtain powder. This powder was placed in capsules to provide capsule preparations.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- The present invention relates to the saccharide derivatives of protocatechualdehyde, the method for preparing thereof, and the use of said derivatives as an anti-inflammatory agent.
- Recently, protocatechualdehyde is attracting attention as an anti-cancer agent (Japanese Patent Laid-open Publication No. 55-51018), as an anti-inflammatory agent (Japanese Patent Laid-open Publication No. 58-83619), and as a nephritis remedy (Japanese Patent Laid-open Publication No. 59-196818).
- In-vitro tests, it has proved that protocatechualdehyde, even when administered at a low concentration level, shows a suitable effect of an anti-inflammatory agent that has a pharmacological action of inhibiting granuloma growth, adjuvant arthritis, leukocytic migration, blood platelet agglutination, and the like; however, in the case of in vivo tests, a large dose of protocatechualdehyde must be administered over a long period due to a higher metabolic rate, in order to obtain a significant pharmacological effect, and moreover, the aldehyde portion of the protocatechualdehyde compound poses excitation and oxidizability problems.
- The present inventors, as a result of research and development of a drug which is administered to live organ requiring only a small dosage to show a significant pharmacological effect with the minimum side-effect, have found that this object can be achieved by the novel saccharide derivatives of protocatechualdehyde having its aldehyde portion reacted to saccharides.
- Consequently, a primary object of the present invention is to provide novel saccharide derivatives of protocatechualdehyde requiring administration of only a small dosage to show favorable pharmacological effects, such as an antiinflammatory effect, with the minimum side-effect, together with the method for preparation and use of said derivatives. Other objects of the present invention will be found out from what is described below.
- The attached Fig. 1 through Fig. 8 show the infrared absorption spectra of the following compounds of the present invention:
- Fig. 1: Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-glucopyranoside
- Fig. 2: Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-glucopyranoside
- Fig. 3: Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-galactopyranoside
- Fig. 4: Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-galactopyranoside
- Fig. 5: Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-mannopyranoside
- Fig. 6: Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-mannopyranoside
- Fig. 7: Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-β-D-glucopyranoside
- Fig. 8: Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-β-D-glucopyranoside
-
- The saccharides shown in the above general formula (I) are hexose that includes for example glucose, mannose, galactose, talose, allose, altrose, idose and gulose. Among them, glucose, galactose and mannose are preferable.
- R² represents an alkyl group protecting the hydroxyl group in 1-position of saccharides. Preferably, R² represents an alkyl group containing 1 to 4 carbon atoms, more preferably 1 to 2 carbon atoms.
- The saccharide derivatives of protocatechualdehyde of the present invention represented by the above general formula (I) include, for example, the following compounds:
Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-glucopyranoside (Ia₁)
Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-glucopyranoside (Ib₁)
Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-β-D-glucopyranoside (Ia₂)
Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-β-D-glucopyranoside (Ib₂)
Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-galactopyranoside (Ia₃)
Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D- galactopyranoside (Ib₃)
Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-β-D-galactopyranoside (Ia₄)
Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-β-D-galactopyranoside (Ib₄)
Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-mannopyranoside (Ia₅)
Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-mannopyranoside (Ib₅)
Methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-β-D-mannopyranoside (Ia₆)
Methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-β-D-mannopyranoside (Ib₆)
Ethyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-glucopyranoside (Ia₇)
Ethyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-glucopyranoside (Ib₇)
n-propyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-glucopyranoside (Ia₈)
n-propyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-glucopyranoside (Ib₈)
i-propyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-glucopyranoside (Ia₉)
i-propyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-glucopyranoside (Ib₉)
n-butyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-glucopyranoside (Ia₁₀)
n-butyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-glucopyranoside (Ib₁₀) -
- The saccharide derivatives of protocatechualdehyde of the present invention may be α-form, β-form, or mixtures thereof. The saccharides in the derivatives of the present invention may be D-form, L-form or mixtures thereof.
- The saccharide derivatives of protocatechualdehyde of the present invention (hereafter called compounds of the present invention) can be produced advantageously by the following method.
- By reacting the acetalized compound (V) derived from acetalization of 3,4-dibenzoyloxybenzaldehyde (II) by using lower alcohol (IV), with the saccharide derivative represented by general formula (III):
-
- The acetalization of the above method for preparing is carried out by dissolving 3,4-dibenzoyloxybenzaldehyde (II) in a lower alcohol(IV) such as methanol or ethanol, then by adding a catalytic amount of p-toluenesulfonic acid or the like and by heating the mixture for 2 to 5 hours under reflux. From the reaction mixture, the lower alcohol (IV) is evaporated, and the residue, or the acetalized compound (V) isolated from the said residue, is reacted with the saccharide derivatives (III).
- The said saccharide derivatives include, for example, 1-O-methylα-D-glucopyranoslde, 1-O-methyl-β-D-glucopyranoside, 1-O-methyl-α-D-galactopyranoside, 1-O-methyl-β-D-galactopyranoside, 1-O-methyl-α-D-mannopyranoside, 1-O-methyl-β-D-mannopyranoside, 1-O-ethyl-α-D-glucopyranoside, 1-O-n-propyl-α-D-glucopyranoslde, 1-O-i-propyl-α-D-glucopyranoside, and 1-O-n-butyl-α-D-glucopyranoside.
- Acetalized compounds of 3,4-dibenzoyloxybenzaldehyde (II) is reacted with saccharide derivatives (III) in an organic solvent in the presence of an acid catalyst at 55-65oC, and this temperature is eventually raised to 80-100oC, while the alcoholic content which is set free is separated and removed and the solvent is refluxed under reduced pressure. Although any organic solvent that does not affect the reaction can be used, usually absolute dimethylformamide or the like is used. As the acid catalyst, p-toluenesulfonic acid or the like is used. After the completion of the reaction, the compound (Ia) of the present invention is obtained by evaporating the organic solvent under reduced pressure, then dissolving the residue in an organic solvent such as ethyl acetate or the like, removing the acid catalyst through washing with a saturated sodium hydrogencarbonate aqueous solution or the like, further removing the organic solvent if necessary, and finally, purifying the product through recrystallization or the like.
- The compound (Ib) of the present invention is obtained by the ammonolysis of the compound (Ia) of the present invention. The ammonolysis is carried out by suspending the compound (Ia) of the present invention in an alcohol such as absolute methanol and then bubbling ammonia gas into the mixture at the room temperature. The ammonia gas is bubbled in slowly to keep the temperature from rising by heat generation.
- The 3,4-dibenzoyloxybenzaldehyde (II) used as a starting material is obtained by dissolving, for example, protocatechualdehyde and triethylamine in dichloromethane and then adding benzoyl chloride dropwise while stirring in an icy water bath.
- Next, the medical applications of the compounds of the present invention are illustrated.
- The compounds of the present invention can be administered orally, intra-intestinally, or by injection in a variety of pharmaceutical preparation forms and formulations combined with medically recognized carriers and/or adjuvants. In this case, two or more compounds of the present invention may be used together in a mixture, or may be used by combinding with any other pharmaceutically active component.
- As the compounds of the present invention can be administered orally or non-orally, it is possible to take different drug forms suitable for respective administration modes. Furthermore, the compounds of the present invention can be supplied on an administration unit form, wherein as long as an effective dosage is contained, a variety of preparation forms are permissible, such as powder, granule, tablet, sugar coated tablet, capsule, suppository, suspension, fluid, emulsion, ampule and injection forms.
- Consequently, the drugs of the present invention should be understood as suppliable by any known means of pharmaceutical preparation. The content of compounds of the present invention (active component) in the preparation of the present invention can vary widely from 0.01 to 100%, preferably from 0.1 to 70% (by weight).
- As above-mentioned, the drugs of the present invention is administered to humans and animals orally or non-orally. In this case, oral administration includes sublingual administration, and non-oral administration includes subcutaneous, intramuscular and intravenous injections and drip infusions.
- As the dosage of the drugs of the present invention varies according to the subject (animal or human), age, individual variation, disease conditions and the like, the drug of the present invention may be administered in an amount outside the range of the dosage indicated below, but in the case of humans, the general oral dosage of compounds of the present invention is 0.1-500 mg per 1 kg of weight per day, preferably 0.5-200 mg, and the general non-oral dosage is 0.01-200 mg per 1 kg of weight per day, preferably 0.1-100 mg, wherein the daily amount is administered in 1-4 divided dosages.
- As stated above, the compounds of the present invention are novel compounds having an inhibiting activity against granuloma growth, a lower toxicity than protocatechualdehyde, and a pharmaceutical effect even with a small dosage.
- Consequently, the compound of the present inven tion are suitable as an anti inflammatory agent for the remedy of chronic articular rheumatism and the like when administered singly or as an active component of pharmaceutical preparations.
- The present invention is further illustrated by following examples.
- 69g of protocatechualdehyde and 111g of triethylamine were dissolved in a 1,500 ml of dichloromethane, then 141g of benzoyl chloride was added dropwise into the solution during a 40 minute period under stirring in a icy water bath. After the dripping, the resultant mixtrue was stirred for 3 hours at the room temperature. The reaction mixture was washed with 1,000 ml of water, with 1,000 ml of 1N hydrochloric acid and then with 1,000 ml of water. The resultant dichloromethane layers were dehydrated and dried with magnesium sulfate, then the dichloromethane was evaporated, and the residue was recrystallized from benzene/hexane and further recrystallized from methanol; finally, 107g of 3,4-dibenzoyloxybenzaldehyde ( 62% yield ) was obtained in the form of crystals having melting point at 101.0-101.8oC. The elementary analysis value of this product was as follows:
Elementary Analysis Value: Found (%) C 72.8, H 4.0 Calculated (%) C 72.8, H 4.0 - 18.5g of the above 3,4-dibenzoyloxybenzaldehyde and 0.35g of p-toluenesulfonic acid were dissolved in a 150 ml of absolute methanol, and after heated for 4 hours under reflux, the methanol was evaporated at 40oC under reduced pressure.
- The evaporating process was continued for an additional 10 minutes after methanol had distilled off. Further attempts were made to remove any remaining methanol by reducing the pressure with a vacuum pump at the room temperature. Although containing a small amount of non-reacted 3,4-dibenzoyloxybenzaldehyde, the residue was used in the next reaction process.
- 11g of 1-O-methyl-α-D-glucopyranoslde and 0.3g of p-toluenesulfonlc acid were added to the residue obtained in the above (2), then the mixture was dissolved in 90 ml of dimethylformamide. The pressure reduction using a rotary evaporator was adjusted in such a way that dimethylformamlde was maintained in a reflux state in a water bath of 60- 65oC, and the reaction was maintained for one hour. Then, the water bath temperature was raised to 85oC to evaporate dimethylformamlde under reduced pressure, and the same temperature level was maintained for an additional 10 minutes after the termination of the dimethylformamide distillation. Then, the residue was dissolved in a 300 ml ethyl acetate, and this solution was washed 2 times with 200 ml saturated aqueous solution of sodium hydrogencarbonate, then 2 times with 200 ml saturated aqueous solution of sodium chloride. The resultant ethyl acetate layer was dehydrated with magnesium sulfate, and then the ethyl acetate was evaporated under reduced pressure. The residue was recrystallized from methanol and was further recrystalllzed from ethyl acetate/n-hexane; finally, 13.9g of methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-glucopyranoside ( 50% yield ) was obtained in the form of crystals having melting point at 152-153oC (In a vacuum sealed tube). The angle of optical rotation, elementary analysis value, infrared absorption spectrum (IR) and ¹H nuclear magnetic resonance spectrum (¹H-NMR) of this product were as follows:
Angle of optical rotation:
[α]D 23.0 =+60o (c 1.0, acetone)Elementary Analysis Value: Found (%) C 64.1, H 5.0 Calculated (%) C 64.4 H 5.0
¹H-NMR (d-acetone, TMS internal standard, ppm):
7.4-8.1 (13H), 5.71 (1H) , 4.73 (1H), 4.25 (1H), 3.7-3.9 (3H), 3.4-3.6 (5H) - 10.8g of methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-glucopyranoside obtained in the above (3) was suspended in 100 ml of absolute methanol, and ammonia gas was bubbled into the suspension to undergo an ammonolysis at the room temperate. The bubbling of ammonia gas was carried out at such a slow pace that the temperature was kept from rising due to a heat generation, and was continued until the heat generation terminated. Then methanol was evaporated under reduced pressure. The sampling of this residue indicated the formation of a compound having an approximate Rf value of 0.3 under silica gel thin layer chromatography (solvent: acetone/
ethyl acetate 1/3 v/v) and turning black when sprayed with alcoholic solutions of ferric chloride. The compounds in question were isolated from the residue by a silica gel column chromatography (solvent: acetone/ethyl acetate 1/3 v/v), and were recrystallized from ethyl acetate; finally, 4.4g of methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-glucopyranoside (68% yield) was obtained in the form of crystals having melting point (decomposed) at 172.5-175.5oC (in a vacuum sealed tube). The angle of optical rotation, elementary analysis value, infrared absorption spectrum (IR), and ¹H nuclear magnetic resonance spectrum (¹H-NMR) of this product were as follows:
Angle of optical rotation:
[α] D 23.5 = +80.0o (c 1.0, methanol)Elementary Analysis Value: Found (%) C 53.3, H 6.0 Calculated (%) C 53.5, H 5.7
¹H-NMR (d-acetone, TMS internal standards, ppm):
6.7-7.0 (3H), 5.42 (1H), 4.71 (1H), 4.14 (1H), 3.6-3.8 (3H) , 3.3-3.5 (5H) - The residue derived from acetalization of 20g of 3,4-dibenzoyloxybenzaldehyde in the same manner as Example 1(2) was reacted with 11.3g of 1-O-methyl-α-D-galactopyranoside in the same manner as Example 1(3), and upon after-treatment, the residue derived from evaporation of ethyl acetate was recrystallized from methanol, and was further recrystallized from ethyl acetate; finally, 14. 1g of methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-galactopyranoside ( 47% yield ) was obtained in the form of crystals having melting point at 186.5-187.5oC (in a vacuum sealed tube). The angle of optical rotation, elementary analysis value, infrared absorption spectrum (IR), and ¹H nuclear magnetic resonance spectrum (¹H-NMR) of this product were as follows:
Angle of optical rotation:
[α] D 23.5 = +84.4o (c 1.0, acetone)Elementary Analysis Value: Found (%) C 64.3, H 5.0 Calculated (%) C 64.4, H 5.0
¹H-NMR (d-acetone, TMS internal standards, ppm):
7.4-8.1 (13H) , 5.73 (1H), 4.75 (1H), 4.32 (1H), 4.1-4.2 (2H) , 3.7-3.9 (3H) , 3.39 (3H) -
- As In Example 1(4), an ammonolysis was carried out by using 14.0g of the methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-galactopyranoside obtained in the above (1). The residue derived from evaporation of methanol was applied with a silica gel column chromatography (solvent: acetone/
ethyl acetate 1/3 v/v), and the portion stained with ferric chloride of silica gel thin-layer chromatography (Rf value of 0.2-0.25) was isolated; then, this portion was recrystallized from acetone/benzene, and finally, 4.9g of methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-galactopyranoside ( 58% yield) was obtained in the form of crystals having melting point (decomposed) at 110-113oC (in a vacuum sealed tube). The angle of optical rotation, elementary analysis value, infrared absorption spectrum (IR), and ¹H nuclear magnetic resonance spectrum (¹H-NMR) of this product were as follows:
Angle of optical rotation:
[α]D 23.7 = +147o (c 1.0, methanol)Elementary Analysis Value: Found (%) C 53.3, H 5.9 Calculated (%) C 53.5, H 5.7
¹H-NMR (d-acetone, TMS internal standards, ppm):
6.7-7.0 (3H), 5.44 (1H), 4.74 (1H), 4.0-4.3 (3H), 3.8-3.9 (2H), 3.66 (1H), 3.39 (3H) - The residue derived from acetalization of 10g of 3,4-dibenzoyloxybenzaldehyde in the same manner as Example 1(2) was reacted with 5.6g of 1-O-methyl-α-D-mannopyranoside in the same manner as Example 1(3), and upon after-treatment, before recrystallization, the residue derived from evaporation of ethyl acetate was isolated by a silica gel column chromatography (solvent: benzene/ethyl acetate 7/3 v/v), then recrystallized from benzene/cyclohexane; finally, 6.1g of methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-mannopyranoside (40% yield) was obtained in the form of crystals having melting point at 166.0-166.7oC (in a vacuum sealed tube). The angle of optical rotation, elementary analysis value, infrared absorption spectrum (IR), and ¹H nuclear magnetic resonance spectrum (¹H-NMR) of this product were as follows:
Angle of optical rotation:
[α]D 23.5 = +28.4o (c 1.0, acetone)Elementary Analysis Value: Found (%) C 64.1, H 4.9 Calculated (%) C 64.4, H 5.0
¹H-NMR (d-acetone, TMS internal standards, ppm):
7.4-8.1 (13H), 5.73 (1H), 4.71 (1H), 4.23 (1H), 3.7-4.0 (5H), 3.38 (3H) - As in Example 1(4), an ammonolysis was carried out by using 3.83g of the methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-mannopyranoside obtained in the above (1). The residue derived from evaporation of methanol was applied with a silica gel column chromatography (solvent: benzene/
ethyl acetate 1/2 v/v), and the portion stained with ferric chloride of silica gel thin-layer chromatography (Rf value of about 0.2) was isolated; then, this portion was dissolved in a thermal acetone, and was crystallized by gradually adding benzene; finally, 1.69g of methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-mannopyranoside (73% yield) was obtained in the form of crystals having melting point ( decomposed) at 120.5-123.0oC (in a vacuum sealed tube). The angle of optical rotation, elementary analysis value, infrared absorption spectrum (IR), and ¹H nuclear magnetic resonance spectrum (¹H-NMR) of this product were as follows:
Angle of optical rotation:
[α]D 23.5 = +32o (c 1.0, methanol)Elementary Analysis Value: Found (%) C 53.4, H 5.7 Calculated (%) C 53.5, H 5.7
¹H-NMR (d-acetone, TMS internal standards, ppm):
6.7-7.0 (3H), 5.44 (1H), 4.68 (1H), 4.13 (1H), 3.6-3.9 (5H), 3.37 (3H) - The residue derived from acetalization of 8g of 3,4-dibenzoyloxybenzaldehyde in the same manner as Example 1(2) was reacted with 4.48g of 1-O-methyl-β-D-glucopyranoside in the same manner as Example 1(3), and upon after-treatment, the residue derived from evaporation of ethyl acetate was recrystallized from methanol, and further recrystallized from ethyl acetate/n-hexane; finally, 5.23g of methyl-4,6-0-(3′,4′-dibenzoyloxybenzylidene)-β-D-glucopyranoside ( 43% yield) was obtained in the form of crystals having melting point at 182-184oC (in a vacuum sealed tube). The angle of optical rotation, elementary analysis value, infrared absorption spectrum (IR), and ¹H nuclear magnetic resonance spectrum (¹H-NMR) of this product were as follows:
Angle of optical rotation:
[α]D 23.5 = -44.0o (c 1.0, acetone)Elementary Analysis Value: Found (%) C 64.1, H 5.0 Calculated (%) C 64.4, H 5.0
¹H-NMR (d-acetone, TMS internal standards, ppm):
7.4-8.1 (13H), 5.72 (1H), 4.2-4.4 (2H), 3.80 (1H), 3.69 (1H), 3.4-3.6 (5H), 3.32 (1H) - As in Example 1(4), an ammonolysis was carried out by using 4.15g of the methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-β-D-glucopyranoside obtained in the above (1). The residue derived from evaporation of methanol was isolated by a silica gel column chromatography. Ethyl acetate/benzene (3/1 v/v) was first used as the solvent, then acetone was used. The portion stained with ferric chloride of silica gel thin-layer chromatography (approximate Rf value of 0.3) was isolated (crude yield: 2.3g), and then, this portion was recrystallized From acetone/benzene (1/1 v/v); finally,1.56g of methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-β-D-glucopyranoside (62% yield) was obtained in the form of crystals having melting point (decomposed) at 175.5-178.0oC (in a vacuum sealed tube). The angle of optical rotation, elementary analysis value, infrared absorption spectrum (IR), and ¹H nuclear magnetic resonance spectrum (¹H-NMR) of this product were as follows:
Angle of optical rotation:
[α]D 23.5 = +74.4o (c 1.0, methanol)Elementary Analysis Value: Found (%) C 53.4, H 5.8 Calculated (%) C 53.5, H 5.7
¹H-NMR (d-acetone, TMS internal standards, ppm):
6.7-7.0 (3H), 5.45 (1H), 4.31 (1H), 4.20 (1H), 3.6-3.8 (2H) , 3.3-3.5 (5H), 3.28 (1H) - This example shows the results of a test on the toxicity and pharmacological characteristics of the compounds of the present invention. As the compounds of the present invention, methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-glucopyranoside [(Ib₁)] and methyl-4,6-O-(3′,4′-dibenzoyloxybenzylidene)-α-D-glucopyranoside [(Ia₁)] were used as test samples. As a control, protocatechualdehyde(PAL) was employed.
- Groups each comprising 5 Jc1:ICR female mice, after oral and intraperitoneal administration, were observed for 7 days, and their LD₅₀ values were determined by the Litchfield-Wilcoxon method.
- The prescribed amounts of the test drugs dispersed In 0.3% CMC aqueous solution at a rate of 20 mg/ml for oral administration and the test drugs dissolved in 10% ethanol isotonic sodium chloride solution at a rate of 200 mg/ml for intraperitoneal administration were applied using gastric probes and syringes, respectively. The results are shown in Table 1.
Table 1 Group LD ₅₀ mg/kg Oral Administration Intraperitoneal Administration (Ib₁) > 4000 > 3000 (Ia₁) > 4000 1900 PAL 1503 404 - Effects of inhibiting granuloma growth were investigated by the method proposed by Fujimura et al. [
O yo Yakuri, 19 (3), 329 (1980)], using five-week old male Donryu rats. As paper disks, filter papers measuring 13 mmø and 28 mg and soaked in 2% CMC solution (containing 0.1 mg/ml of 1 million unit dihydroxystreptomycin and penicillin, respectively) were used. A paper disk was implanted subcutaneously in the back of the rat under anesthesia. The test drugs dispersed in 0.3% CMC solutions were administered orally for 10 days; then, on the 11th day the granulomas were removed and their weights were measured. To the control group were administered the original 0.3% CMC solution containing no test drug. - As shown in Table 2, the results of this test indicated that the compounds of the present invention inhibit granuloma growth with a dosage smaller than that of PAL.
- According to a reference (DRUGS IN JAPAN(ETHICAL DRUGS), 9th Edition (1985), YAKUGYO JIHO CO., LTD., p.105), the LD₅₀ value of indomethacin, which was used as a positive control in this test, is 30.2 mg/kg for male mice and 29 mg/kg for male rats, and therefore, indomethacin is more toxic than both PAL and the compounds of the present invention.
- Other compounds of the present invention obtained in accordance with the aforementioned Examples 2-4 also indicated a similar effect of inhibiting granuloma growth.
Table 2 Group Dosage (mg/kg/day) No. of rats Granuloma Dry weight(mg) (mean) Inhibition rate(%) Control - 4 131.9 - Compounds of the present invention (Ib₁) 10 6 91.4 30.7 50 6 66.0 50.0 (Ia₁) 10 4 92.6 29.8 50 6 74.3 43.7 Positive control Indomethacin 3 5 71.3 45.9 PAL 50 6 86.8 34.2 - This example shows the pharmaceutical preparation of compounds of the present invention.
Compound of the present invention [methyl-4,6-O-(3′,4′-dihydroxybenzylidene)-α-D-glucopyranoside] 10 weight parts Heavy magnesium oxide 15 weight parts Lactose 75 weight parts
Claims (7)
- (2) Methods for preparing saccharide derivatives of protocatechualdehyde represented by general formula (I):
- (3) Method for preparing according to Claim (2), wherein the above acetalized compound and the saccharide derivative represented by general Formula (III) are reacted in an organic solvent in the presence of an acid catalyst.
- (4) Method for preparing according to Claim (2) or (3), wherein the react ion is carried out at a temperature of 55-65oC, which is eventually raised to 80-100oC.
- (6) Pharmaceutical compositions which comprise, as an active component, saccharide derivatives of protocatechualdehyde represented by the formula (I):
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP200903/89 | 1989-08-02 | ||
JP1200903A JPH0363224A (en) | 1989-08-02 | 1989-08-02 | Sugar derivative of protocatechuic aldehydes |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0411624A2 true EP0411624A2 (en) | 1991-02-06 |
EP0411624A3 EP0411624A3 (en) | 1991-11-06 |
EP0411624B1 EP0411624B1 (en) | 1993-07-07 |
Family
ID=16432179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP90114847A Expired - Lifetime EP0411624B1 (en) | 1989-08-02 | 1990-08-02 | Saccharide derivatives of protocatechualdehyde |
Country Status (11)
Country | Link |
---|---|
US (1) | US5120835A (en) |
EP (1) | EP0411624B1 (en) |
JP (1) | JPH0363224A (en) |
KR (1) | KR920007273B1 (en) |
CN (1) | CN1023646C (en) |
AU (1) | AU621504B2 (en) |
CA (1) | CA2022516C (en) |
DE (1) | DE69002136T2 (en) |
DK (1) | DK0411624T3 (en) |
NO (1) | NO170854C (en) |
ZA (1) | ZA906008B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19524515A1 (en) * | 1995-07-05 | 1997-01-09 | Deutsches Krebsforsch | Saccharide conjugates |
WO2004067009A1 (en) * | 2003-01-29 | 2004-08-12 | Dal-Hoon Son | Pharmaceutical composition comprising an extract or compounds isolated from elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2824157B1 (en) * | 2012-03-08 | 2020-02-12 | Kyushu University | Novel sugar-derived gelling agent |
CN108003357B (en) * | 2017-11-13 | 2020-07-07 | 西南大学 | Catechul cross-linked collagen hydrogel and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5883619A (en) * | 1981-11-11 | 1983-05-19 | Kureha Chem Ind Co Ltd | Anti-inflammatory agent |
JPS58203999A (en) * | 1982-05-24 | 1983-11-28 | Kaken Pharmaceut Co Ltd | Preparation of glucose compound |
EP0166443A2 (en) * | 1984-06-28 | 1986-01-02 | Kaken Pharmaceutical Co., Ltd. | Benzaldehyde and 4,6-0-benzylidene-D-glucose for alleviating pain |
JPS617234A (en) * | 1984-06-22 | 1986-01-13 | Kureha Chem Ind Co Ltd | Dialkanoyloxybenzylidene dialkanoate |
EP0215395A2 (en) * | 1985-09-06 | 1987-03-25 | Kaken Pharmaceutical Co., Ltd. | Pharmaceutical composition for retarding and reducing cachexia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4165341A (en) * | 1977-02-04 | 1979-08-21 | Ube Industries, Ltd. | Process for preparing protocatechualdehyde and its derivatives |
JPS59193822A (en) * | 1983-04-15 | 1984-11-02 | Kureha Chem Ind Co Ltd | Remedy for nephritis |
-
1989
- 1989-08-02 JP JP1200903A patent/JPH0363224A/en active Pending
-
1990
- 1990-07-18 US US07/555,064 patent/US5120835A/en not_active Expired - Fee Related
- 1990-07-31 ZA ZA906008A patent/ZA906008B/en unknown
- 1990-07-31 CN CN90106611A patent/CN1023646C/en not_active Expired - Fee Related
- 1990-08-01 AU AU60075/90A patent/AU621504B2/en not_active Ceased
- 1990-08-01 KR KR1019900011667A patent/KR920007273B1/en not_active IP Right Cessation
- 1990-08-01 NO NO903397A patent/NO170854C/en unknown
- 1990-08-02 DE DE90114847T patent/DE69002136T2/en not_active Expired - Fee Related
- 1990-08-02 EP EP90114847A patent/EP0411624B1/en not_active Expired - Lifetime
- 1990-08-02 DK DK90114847.8T patent/DK0411624T3/en active
- 1990-08-02 CA CA002022516A patent/CA2022516C/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5883619A (en) * | 1981-11-11 | 1983-05-19 | Kureha Chem Ind Co Ltd | Anti-inflammatory agent |
JPS58203999A (en) * | 1982-05-24 | 1983-11-28 | Kaken Pharmaceut Co Ltd | Preparation of glucose compound |
JPS617234A (en) * | 1984-06-22 | 1986-01-13 | Kureha Chem Ind Co Ltd | Dialkanoyloxybenzylidene dialkanoate |
EP0166443A2 (en) * | 1984-06-28 | 1986-01-02 | Kaken Pharmaceutical Co., Ltd. | Benzaldehyde and 4,6-0-benzylidene-D-glucose for alleviating pain |
EP0215395A2 (en) * | 1985-09-06 | 1987-03-25 | Kaken Pharmaceutical Co., Ltd. | Pharmaceutical composition for retarding and reducing cachexia |
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, vol. 88, no. 25, 19th June 1978, page 816, column 2, abstract no. 191326k, Columbus, Ohio, US; D. JONIAK et al.: "Preparation of some methyl alpha-D-glucopyranoside cyclic acetals by transacetalation", & CHEM. ZVESTI 1977, 31(1), 106-8 * |
PATENT ABSTRACTS OF JAPAN, vol. 10, no. 148 (C-350)[2205], 29th May 1986; & JP-A-61 007 234 (KUREHA KAGAKU KOGYO K.K.) 13-01-1986 * |
PATENT ABSTRACTS OF JAPAN, vol. 7, no. 175 (C-179)[1320], 3rd August 1983; & JP-A-58 083 619 (KUREHA KAGAKU KOGYO K.K.) 19-05-1983 (Cat. D) * |
PATENT ABSTRACTS OF JAPAN, vol. 8, no. 46 (C-212)[1483], 29th February 1984; & JP-A-58 203 999 (KAKEN SEIYAKU K.K.) 28-11-1983 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19524515A1 (en) * | 1995-07-05 | 1997-01-09 | Deutsches Krebsforsch | Saccharide conjugates |
WO2004067009A1 (en) * | 2003-01-29 | 2004-08-12 | Dal-Hoon Son | Pharmaceutical composition comprising an extract or compounds isolated from elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications |
US7595055B2 (en) | 2003-01-29 | 2009-09-29 | Dal-Hoon Son | Pharmaceutical composition comprising an extract or compounds isolated from Elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications |
Also Published As
Publication number | Publication date |
---|---|
KR920003836A (en) | 1992-02-29 |
CN1023646C (en) | 1994-02-02 |
AU621504B2 (en) | 1992-03-12 |
EP0411624A3 (en) | 1991-11-06 |
US5120835A (en) | 1992-06-09 |
AU6007590A (en) | 1991-08-01 |
DE69002136D1 (en) | 1993-08-12 |
NO903397D0 (en) | 1990-08-01 |
NO170854C (en) | 1992-12-16 |
DE69002136T2 (en) | 1993-10-14 |
ZA906008B (en) | 1991-05-29 |
EP0411624B1 (en) | 1993-07-07 |
CA2022516C (en) | 1995-08-22 |
NO170854B (en) | 1992-09-07 |
NO903397L (en) | 1991-02-04 |
CA2022516A1 (en) | 1991-02-03 |
CN1049346A (en) | 1991-02-20 |
DK0411624T3 (en) | 1993-08-16 |
KR920007273B1 (en) | 1992-08-29 |
JPH0363224A (en) | 1991-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05194470A (en) | Anti-endotoxin compound | |
US4251520A (en) | Glucofuranose derivatives | |
KR970002905B1 (en) | S-(lower fatty acid)-substituted glutathione derivative | |
JPS608000B2 (en) | Aminophenyl derivatives and bioactive agents containing the derivatives | |
US6093697A (en) | Synthetic insulin mimetic substances | |
Vis et al. | 1, 5-Anhydro-β-D-ribofuranose and the “Monoacetone Anhydroriboses” of Levene and Stiller | |
EP0411624B1 (en) | Saccharide derivatives of protocatechualdehyde | |
US4801581A (en) | Pharmaceutical composition containing para-amino-benzoic acid-N-D-xyloside as an active ingredient | |
AU596800B2 (en) | Improvements in or relating to organic compounds | |
US4148921A (en) | Antitumor agents | |
CA2075336A1 (en) | 3-deoxy-mannosamine derivatives and process for their preparation | |
US4503045A (en) | 2'-Deoxy-3',5'-di-O-alkylcarbonyl-5-fluorouridine derivatives, a process for the preparation of the derivatives and anti-tumor agents containing the derivatives | |
US3718680A (en) | Phosphine or phosphite gold complexes of thioethanol and derivatives thereof | |
IE63517B1 (en) | Saccharide derivatives | |
EP0424543A1 (en) | New s-adenosylmethionine derivative | |
US4476299A (en) | Cyclic polyamino containing compounds having therapeutic effect and the preparation thereof | |
JPH09169648A (en) | Medicine composition | |
US4235803A (en) | 1,6-Dimesyl-3,4-dimethyl-D-mannitol and a process for the preparation thereof | |
US4895935A (en) | Platinum pharmaceuticals | |
EP0056458B1 (en) | Nitrosourea derivatives, a process for preparing same and therapeutic compositions | |
US4698331A (en) | 2,3-diamino-2,3-didesoxyhexose derivatives and their use | |
JP4182218B2 (en) | Novel glucose derivative that induces apoptosis, process for its production and its use as a medicament | |
JPH0370700B2 (en) | ||
US4647412A (en) | Anti-tumor derivatives of butanediol and process of preparation | |
CA1261850A (en) | Homocarnosine or acylhomocarnosine salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19900802 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): BE CH DE DK FR GB IT LI NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): BE CH DE DK FR GB IT LI NL SE |
|
17Q | First examination report despatched |
Effective date: 19911223 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE DK FR GB IT LI NL SE |
|
ET | Fr: translation filed | ||
REF | Corresponds to: |
Ref document number: 69002136 Country of ref document: DE Date of ref document: 19930812 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
ITF | It: translation for a ep patent filed |
Owner name: STUDIO CONS. BREVETTUAL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
EAL | Se: european patent in force in sweden |
Ref document number: 90114847.8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19960724 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 19960807 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19960809 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19960812 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19960815 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19960821 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19960828 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19961003 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970802 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970802 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970831 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970831 |
|
BERE | Be: lapsed |
Owner name: KUREHA CHEMICAL INDUSTRY CO. LTD Effective date: 19970831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980301 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19970802 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980501 |
|
EUG | Se: european patent has lapsed |
Ref document number: 90114847.8 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19980301 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050802 |